Peak Bio, Inc.

Peak Bio, Inc. (Nasdaq: PKBO) is a clinical-stage biopharmaceutical company that entered the public markets in 2023 through a business combination with Apex Healthcare Acquisition Corp, a healthcare-focused special purpose acquisition company. The company is developing antibody-based therapeutics aimed at oncology and inflammatory disease indications, placing it squarely in the biotechnology sector. On November 14, 2024, Peak Bio filed an 8-K current report with the SEC, disclosing a material corporate event as required under exchange reporting obligations. Like many de-SPAC companies, Peak Bio has been navigating the post-merger public-company environment since its listing. For full filing histories, SPAC deal analytics, and real-time event tracking on PKBO, sign up for complete data access at SpacDesk.